ROG NYSE
Rogers Corporation
1W: +16.3%
1M: +29.2%
3M: +13.6%
YTD: +74.3%
1Y: +95.9%
3Y: +23.5%
5Y: -16.0%
$160.00
+4.20 (+2.70%)
Weekly Expected Move ±6.9%
$138
$149
$160
$171
$182
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.75
Bullish
5 bullish
1 neutral
0 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (100)
Rogers (NYSE:ROG) Stock Jumps 8.7% – Time to Buy?
Rogers Corp. (ROG) Moves 10.7% Higher: Will This Strength Last?
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
Rogers Corporation climbs 11% to reach multi-month high
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Änderung im Verwaltungsrat von Roche
Change in Roche’s Board of Directors
Tidal Investments LLC Sells 7,103 Shares of Rogers Corporation $ROG
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Engineers Gate Manager LP Buys 6,639 Shares of Rogers Corporation $ROG
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
Connor Clark & Lunn Investment Management Ltd. Takes $773,000 Position in Rogers Corporation $ROG
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
BlackRock Inc. Takes Position in Rogers Corporation $ROG
Rogers Corp. (ROG) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
Starboard adds Dynatrace, Flowserve, and exits Beckton Dickson, among top Q2 trades
How Much Upside is Left in Rogers Corp. (ROG)? Wall Street Analysts Think 25.08%
nVent Electric Rises 46% in 6 Months: Buy, Sell or Hold the Stock?
All You Need to Know About Rogers Corp. (ROG) Rating Upgrade to Buy
Rogers Corporation (NYSE: ROG) swings to profit as Q2 2026 margins improve - Stock Titan
Rogers forecasts Q3 revenue of $233M-$243M with 19.7% adjusted EBITDA margin amid China ramp headwinds
Rogers Corp. (ROG) Q2 Earnings Miss Estimates
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens
TTM Technologies (TTMI) to Report Q2 Results: Wall Street Expects Earnings Growth
Rogers (NYSE:ROG) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
What This Rogers Corp Insider Transaction Means With EPS Up 178%
Rogers Corporation Schedules Second Quarter 2026 Earnings Call for July 28 - Business Wire
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Roche receives CE Mark for blood test to identify tuberculosis infection
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Best Momentum Stocks to Buy for June 25th
New Strong Buy Stocks for June 25th
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Rogers Corp. (ROG) Surges 4.0%: Is This an Indication of Further Gains?
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
NVT Surges 53% in 3 Months: Should You Buy, Sell or Hold the Stock?
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
Rogers Corp. (ROG) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Is Rogers Corporation (ROG) A Good Stock To Buy Now?
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rogers Corp. SVP Sells 830 Shares Worth $113,000 as the Stock Continues Its Climb. Time to Sell?
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Rogers Corp. (ROG) is a Great Momentum Stock: Should You Buy?
Meta, Ford, Willis Towers Watson And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Rogers Corporation Q1 2026 Earnings Call Summary
Rogers (ROG) Q1 2026 Earnings Call Transcript
Rogers forecasts Q2 adjusted EPS of $0.90 to $1.10 with adjusted EBITDA margin at 17.7% midpoint
Rogers Corp. (ROG) Q1 Earnings Beat Estimates
Rogers Q1 2026 Earnings Call: Complete Transcript
Rogers Corporation (NYSE: ROG) lifts Q1 2026 margins and posts quarterly profit - Stock Titan
Rogers Non-GAAP EPS of $0.75 beats by $0.07, revenue of $200.5M in-line
Rogers (ROG) Q2 2025 Earnings Call Transcript
Here are the major earnings after the close Tuesday
Earnings Scheduled For April 28, 2026
Rogers (NYSE:ROG) Shares Gap Up – Should You Buy?
Rogers Corp. (ROG) Soars 6.4%: Is Further Upside Left in the Stock?
Texas Instruments jumps as data center revenue surges 90%; leads analog stocks higher
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
Rogers (NYSE:ROG) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
Roche eröffnet neues Forschungsgebäude für das Institute of Human Biology und leistet damit Pionierarbeit im Bereich menschlicher Modellsysteme, um Entwicklung von Medikamenten zu beschleunigen
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Cinctive Capital Management LP Invests $5.34 Million in Rogers Corporation $ROG
Roche Generalversammlung 2026
Assemblée générale annuelle 2026 de Roche
Roche Annual General Meeting 2026
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Clearline Capital Increases Core Scientific Stake as Bitcoin Mining Becomes a Data Center Business
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Clearline Capital Trims Semtech as Post-Sierra Model Drives Earnings
Media Mogul Tom Rogers: Netflix has a great path ahead after freeing itself from Warner Bros. deal
The Great Canadian Jersey Coming to the Hockey Hall of Fame